Eikon Therapeutics Set for Russell 3000 Inclusion After June 26 Reconstitution
EIKN•EIKN•EIKN•EIKN•Eikon Therapeutics will join the Russell 3000 Index after US market close on June 26, 2026, placing the company among the 3,000 stocks representing 98% of the investable US equity market. This inclusion could boost Eikon’s institutional ownership, enhance liquidity and improve market visibility.
Eikon Therapeutics will be added to the Russell 3000 Index following the annual reconstitution, effective after US market close on June 26, 2026. The Russell 3000 measures performance of approximately 3,000 large-, mid- and small-cap US equities, representing roughly 98% of the investable US equity market.
Inclusion in the Russell 3000 typically triggers passive fund inflows and can broaden institutional ownership. For Eikon, this milestone is expected to enhance stock liquidity, increase market visibility and potentially narrow bid-ask spreads as more benchmarked investors gain exposure.
